

Optimierung der Thiopurintherapie bei CED-Patienten

Kasuistik und Erfahrungsbericht aus einer gastroenterologischen Praxis

Dr. Henrich Wenzel (Gastroenterologiepraxis Wuppertal)

¹ Optimizing the use of thiopurines in inflammatory bowel disease. Rishi M. Goel et.al., Ther Adv Chronic Dis 2015, Vol. 6(3): 138–146.

² Thiopurine metabolites in the management of patients with inflammatory bowel disease: a single centre experience of 100 samples. Hall, P S J et.al, Gut 2013;62: A4, Oral Presentations 8.

³ Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Sparrow MP, et. al., Clin Gastroenterol Hepatol. 2007 Feb;5(2): 209-14.

⁴ Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. Melissa A. Smith et.al., Journal of Crohn's and Colitis (2012) 6: 905–912.

⁵ Randomised clinical trial: individualized versus weight-based dosing of azathioprine in crohn's disease. Themistocles Dassopoulos, M.D. et.al., Aliment Pharmacol Ther. 2014 January; 39(2): 163–175.